EMA’s Clinical Data Disclosure Plan Under Fire The European Medicines Agency really is between a rock and a hard place. It might have expected the publication of its plan for proactive release of clinical reports to receive a warm welcome. The plan is, after all, a judicious blend of ambition and caution. But the outcome is far from a roaring success, writes Reflector. Read more
How Do You Solve a Problem Like England’s Cancer Drug Fund? England’s Cancer Drugs Fund (CDF) deals with rejections by the National Institute for Health and Care Excellence (NICE) for new cancer medicines. Now worth £280 million a year, it started out with positive headlines, but over time it’s fallen out of favor, writes Leela Barham... Read more
The Human Microbiome — Our Body’s Secret Weapon A collective group of scientists and researchers are just beginning to unlock the full power of the human microbiome, the collective genomes of all microorganisms present in or on the human body. It’s an exciting time, writes Lee Jones... Read more
Pharm Exec Global: US Healthcare Reform Special In the latest issue of the Pharm Exec Global Digest: Dealing with the “side effects” of Obamacare; The “value” of Rxs under Obamacare; The escalating cost of US oncology care; And more .... Read more
